Developer docs
API playgroundTry for free, no card

Search company profiles

InflaRx

Full company profile

uuid0003727

Namestring
InflaRx
Legal namestring
InflaRx N.V.
Websiteurl
inflarx.de
Company typeenum
Public
Founded yearint
2007
Descriptiontext

InflaRx N.V. is a clinical-stage biopharmaceutical company founded in 2007 in Jena, Germany, and listed on Nasdaq under ticker IFRX since 2017. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover and develop highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR, targeting life-threatening and debilitating inflammatory diseases with high unmet medical need. Its lead clinical asset, vilobelimab (brand: GOHIBIC), is a first-in-class intravenously delivered anti-C5a monoclonal antibody that received FDA Emergency Use Authorization in April 2023 for treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO. The second key asset, izicopan (INF904), is an orally administered small molecule C5aR1 inhibitor in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, and — as of May 2026 — ANCA-associated vasculitis and select renal diseases (aHUS, IgA nephropathy, C3 glomerulopathy). A third candidate, IFX002, is part of the pipeline alongside the underlying C5a/C5aR complement platform.

InflaRx operates a classic clinical-stage biotech business model with no fully approved commercial products and no material recurring product revenue. Revenue mechanics are dominated by capital markets: post-IPO equity raises totaling approximately $220M between 2023 and 2026 ($40M April 2023, $30M February 2025, $150M May 2026), supplemented by a modest licensing arrangement with Staidson BioPharma for BDB-001 in China ($2.5M investment plus future royalties). Distribution of GOHIBIC under EUA is handled through authorized pharmaceutical distributors to US hospitals and ICUs. The company employs 101-250 staff across Jena (headquarters), Munich/Martinsried, and Ann Arbor, Michigan, and was led in January 2026 through a strategic restructuring with approximately 30% workforce reduction to prioritize izicopan development and extend cash runway to mid-2027, with management stating sufficient funds to execute planned clinical development through 2029.

Short descriptiontext

InflaRx is a clinical-stage biopharmaceutical company developing proprietary anti-C5a and anti-C5aR inhibitors for life-threatening inflammatory diseases; its lead assets are GOHIBIC (vilobelimab, FDA EUA for COVID-19) and izicopan, an oral C5aR1 inhibitor in development for hidradenitis suppurativa, ANCA-associated vasculitis, and renal diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJena, Germany
HQ citystring
Jena
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
complement system inhibitors, anti-inflammatory therapeutics, monoclonal antibody drugs, biopharmaceutical development, inflammatory disease treatments
Industry3 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAHAA
Immunoglobulins (IVIG/SCIG)
SECONDARYHLAKAEAA
General Gastroenterology
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1GOHIBIC (Vilobelimab) Emergency Use
TypeOne Time License
Description

GOHIBIC received Emergency Use Authorization from FDA in April 2023 for treatment of COVID-19 in hospitalized adults. Revenue generated from product sales to healthcare institutions.

inflarx.de
2Licensing and Royalties (BDB-001/China)
TypeLicensing Royalties
Description

Partnership with Staidson BioPharma for BDB-001 in China generates USD 2.5 million investment and potential royalties on future sales.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1GOHIBIC
Description

Brand name for vilobelimab, an anti-C5a monoclonal antibody authorized under FDA Emergency Use Authorization for COVID-19 treatment in hospitalized adults.

inflarx.de
Core offering1 text field

InflaRx is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutics targeting the complement system's C5a and C5aR signaling pathway. Its lead authorized product is GOHIBIC (vilobelimab), an intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for treating COVID-19 in hospitalized adults on mechanical ventilation or ECMO. Its pipeline lead is izicopan (INF904), an oral small molecule C5aR1 inhibitor in development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select renal diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ≥90% blockade of C5a-induced neutrophil activation achieved over 14-day dosing period with izicopan
+3 more records
Product overview1 text field

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system. The company's product portfolio centers on two main drug candidates: GOHIBIC (vilobelimab), a first-in-class intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for COVID-19, and izicopan (INF904), an orally administered small molecule C5a receptor inhibitor in clinical development for multiple inflammatory diseases. The company leverages its proprietary complement platform technology to develop treatments for life-threatening or debilitating inflammatory conditions with high unmet medical need.

Product and service3 records
1GOHIBIC (vilobelimab)
CategoryAnti-C5a monoclonal antibody (biologic)
Description

First-in-class, intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a, for the treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO under FDA Emergency Use Authorization; sold to US hospitals and healthcare institutions.

2Izicopan (INF904)
CategoryOral C5aR small molecule inhibitor
Description

Orally administered small molecule inhibitor of the C5a receptor (C5aR1) in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select complement-mediated renal diseases; designed for differentiated pharmacological properties with potential best-in-class efficacy and safety.

3IFX002
CategoryPipeline candidate (complement inhibitor)
Description

Pipeline candidate in InflaRx's complement-mediated inflammatory disease development program, disclosed alongside vilobelimab and izicopan in the company's R&D pipeline.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Staidson BioPharma Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-21
Description

Partnership amended in December 2022 to support regulatory approval process in China for BDB-001, an anti-C5a antibody for COVID-19. InflaRx received USD 2.5 million investment from STS with option for additional funding and will receive royalties on future sales of BDB-001 in China.

biospace.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1ChemoCentryx (Amgen)
TypeDirect peer
Description

Developer of avacopan, the first FDA-approved oral C5aR inhibitor for ANCA-associated vasculitis, acquired by Amgen in 2022. The closest direct competitor to InflaRx's izicopan, targeting the same receptor in overlapping inflammatory indications.

TypeDirect peer
Description

Complement franchise leader with Soliris and Ultomiris (C5 inhibitors) for PNH, aHUS, and gMG. Competes in the same complement-mediated inflammatory disease space with established global commercialization and rare-disease infrastructure.

TypeDirect peer
Description

Commercial-stage complement therapeutics company with Empaveli (C3 inhibitor for PNH) and Syfovre (geographic atrophy). Targets complement-mediated diseases through a different but overlapping mechanism, comparable in indication focus.

TypeDirect peer
Description

Clinical-stage company developing narsoplimab, an anti-MASP-2 antibody targeting the lectin pathway of complement. Small-cap complement therapeutics peer with similar profile of clinical-stage assets and reliance on capital markets.

TypeEmerging player
Description

Commercial-stage rare-disease company with Orladeyo (hereditary angioedema) and an oral kallikrein inhibitor franchise. Operates in the complement-adjacent inflammation/rare-disease space with similar size and growth profile.

TypeBroad incumbent
Description

European-based rare-disease and specialty biopharma with presence in inflammation and hematology. A relevant board-member connection (former President Europe/MENAR) and broader portfolio targeting complement and inflammatory pathways.

TypeBroad incumbent
Description

Global biopharmaceutical major that acquired ChemoCentryx and now markets avacopan. Represents both the direct C5aR competition and a potential strategic acquirer given its inflammation/rare-disease franchise build-out.

TypeBroad incumbent
Description

Owns Alexion's complement franchise (Soliris/Ultomiris) and has commercial infrastructure for rare inflammatory diseases. A natural potential acquirer or partner for InflaRx given overlapping therapeutic area and global reach.

TypeBroad incumbent
Description

Global biopharma with rare-disease and immunology franchises acquired through Shire. Has commercial scale in complement-adjacent indications and a track record of mid-cap biotech acquisitions.

TypeBroad incumbent
Description

Global biopharma with multiple complement programs and an inflammation/immunology portfolio. Represents a potential strategic acquirer for late-stage C5aR assets and a comparable benchmark for cross-border biopharma valuation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InflaRx

Inflammatory Disease Therapeuticsinflarx.de

InflaRx is a clinical-stage biopharmaceutical company developing proprietary anti-C5a and anti-C5aR inhibitors for life-threatening inflammatory diseases; its lead assets are GOHIBIC (vilobelimab, FDA EUA for COVID-19) and izicopan, an oral C5aR1 inhibitor in development for hidradenitis suppurativa, ANCA-associated vasculitis, and renal diseases.

What InflaRx does

InflaRx N.V. is a clinical-stage biopharmaceutical company founded in 2007 in Jena, Germany, and listed on Nasdaq under ticker IFRX since 2017. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover and develop highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR, targeting life-threatening and debilitating inflammatory diseases with high unmet medical need. Its lead clinical asset, vilobelimab (brand: GOHIBIC), is a first-in-class intravenously delivered anti-C5a monoclonal antibody that received FDA Emergency Use Authorization in April 2023 for treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO. The second key asset, izicopan (INF904), is an orally administered small molecule C5aR1 inhibitor in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, and — as of May 2026 — ANCA-associated vasculitis and select renal diseases (aHUS, IgA nephropathy, C3 glomerulopathy). A third candidate, IFX002, is part of the pipeline alongside the underlying C5a/C5aR complement platform.

InflaRx operates a classic clinical-stage biotech business model with no fully approved commercial products and no material recurring product revenue. Revenue mechanics are dominated by capital markets: post-IPO equity raises totaling approximately $220M between 2023 and 2026 ($40M April 2023, $30M February 2025, $150M May 2026), supplemented by a modest licensing arrangement with Staidson BioPharma for BDB-001 in China ($2.5M investment plus future royalties). Distribution of GOHIBIC under EUA is handled through authorized pharmaceutical distributors to US hospitals and ICUs. The company employs 101-250 staff across Jena (headquarters), Munich/Martinsried, and Ann Arbor, Michigan, and was led in January 2026 through a strategic restructuring with approximately 30% workforce reduction to prioritize izicopan development and extend cash runway to mid-2027, with management stating sufficient funds to execute planned clinical development through 2029.

InflaRx firmographics

Firmographics
Name
InflaRx
Legal name
InflaRx N.V.
Website
https://inflarx.de
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
InflaRx is a clinical-stage biopharmaceutical company developing proprietary anti-C5a and anti-C5aR inhibitors for life-threatening inflammatory diseases; its lead assets are GOHIBIC (vilobelimab, FDA EUA for COVID-19) and izicopan, an oral C5aR1 inhibitor in development for hidradenitis suppurativa, ANCA-associated vasculitis, and renal diseases.
Ownership category
akta.pro rank

InflaRx industry classification

Industry
Product category
Inflammatory Disease Therapeutics
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAHAA
Immunoglobulins (IVIG/SCIG)
SECONDARYHLAKAEAA
General Gastroenterology

Keywords

  • Complement system inhibitors
  • Anti-inflammatory therapeutics
  • Monoclonal antibody drugs
  • Biopharmaceutical development
  • Inflammatory disease treatments

Where InflaRx is headquartered

Location

Headquarters

HQ city
Jena
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

InflaRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. GOHIBIC (Vilobelimab) Emergency Use: GOHIBIC received Emergency Use Authorization from FDA in April 2023 for treatment of COVID-19 in hospitalized adults. Revenue generated from product sales to healthcare institutions.
  2. Licensing and Royalties (BDB-001/China): Partnership with Staidson BioPharma for BDB-001 in China generates USD 2.5 million investment and potential royalties on future sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

InflaRx product offering

Product offering

Core offering

InflaRx is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutics targeting the complement system's C5a and C5aR signaling pathway. Its lead authorized product is GOHIBIC (vilobelimab), an intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for treating COVID-19 in hospitalized adults on mechanical ventilation or ECMO. Its pipeline lead is izicopan (INF904), an oral small molecule C5aR1 inhibitor in development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select renal diseases.

Product overview

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system. The company's product portfolio centers on two main drug candidates: GOHIBIC (vilobelimab), a first-in-class intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for COVID-19, and izicopan (INF904), an orally administered small molecule C5a receptor inhibitor in clinical development for multiple inflammatory diseases. The company leverages its proprietary complement platform technology to develop treatments for life-threatening or debilitating inflammatory conditions with high unmet medical need.

Differentiator

Problem solved

Functional benefit

Brands

  • GOHIBIC: Brand name for vilobelimab, an anti-C5a monoclonal antibody authorized under FDA Emergency Use Authorization for COVID-19 treatment in hospitalized adults.

Products and services

  • GOHIBIC (vilobelimab) First-in-class, intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a, for the treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO under FDA Emergency Use Authorization; sold to US hospitals and healthcare institutions.
  • Izicopan (INF904) Orally administered small molecule inhibitor of the C5a receptor (C5aR1) in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select complement-mediated renal diseases; designed for differentiated pharmacological properties with potential best-in-class efficacy and safety.
  • IFX002 Pipeline candidate in InflaRx's complement-mediated inflammatory disease development program, disclosed alongside vilobelimab and izicopan in the company's R&D pipeline.

Quantifiable outcome

  • ≥90% blockade of C5a-induced neutrophil activation achieved over 14-day dosing period with izicopan
  • +3 more outcomes

Companies that use InflaRx

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

InflaRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

InflaRx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Staidson BioPharma Inc.coreStrategic or Co-development Partner · 21 December 2022Partnership amended in December 2022 to support regulatory approval process in China for BDB-001, an anti-C5a antibody for COVID-19. InflaRx received USD 2.5 million investment from STS with option for additional funding and will receive royalties on future sales of BDB-001 in China.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

InflaRx competitors and assessment

Company assessment

Direct peers

  • ChemoCentryx (Amgen): Developer of avacopan, the first FDA-approved oral C5aR inhibitor for ANCA-associated vasculitis, acquired by Amgen in 2022. The closest direct competitor to InflaRx's izicopan, targeting the same receptor in overlapping inflammatory indications.
  • Alexion (AstraZeneca Rare Disease): Complement franchise leader with Soliris and Ultomiris (C5 inhibitors) for PNH, aHUS, and gMG. Competes in the same complement-mediated inflammatory disease space with established global commercialization and rare-disease infrastructure.
  • Apellis Pharmaceuticals: Commercial-stage complement therapeutics company with Empaveli (C3 inhibitor for PNH) and Syfovre (geographic atrophy). Targets complement-mediated diseases through a different but overlapping mechanism, comparable in indication focus.
  • Omeros Corporation: Clinical-stage company developing narsoplimab, an anti-MASP-2 antibody targeting the lectin pathway of complement. Small-cap complement therapeutics peer with similar profile of clinical-stage assets and reliance on capital markets.

Emerging players

  • BioCryst Pharmaceuticals: Commercial-stage rare-disease company with Orladeyo (hereditary angioedema) and an oral kallikrein inhibitor franchise. Operates in the complement-adjacent inflammation/rare-disease space with similar size and growth profile.

Broad incumbents

  • Swedish Orphan Biovitrum (Sobi): European-based rare-disease and specialty biopharma with presence in inflammation and hematology. A relevant board-member connection (former President Europe/MENAR) and broader portfolio targeting complement and inflammatory pathways.
  • Amgen: Global biopharmaceutical major that acquired ChemoCentryx and now markets avacopan. Represents both the direct C5aR competition and a potential strategic acquirer given its inflammation/rare-disease franchise build-out.
  • AstraZeneca: Owns Alexion's complement franchise (Soliris/Ultomiris) and has commercial infrastructure for rare inflammatory diseases. A natural potential acquirer or partner for InflaRx given overlapping therapeutic area and global reach.
  • Takeda Pharmaceutical: Global biopharma with rare-disease and immunology franchises acquired through Shire. Has commercial scale in complement-adjacent indications and a track record of mid-cap biotech acquisitions.
  • Novartis: Global biopharma with multiple complement programs and an inflammation/immunology portfolio. Represents a potential strategic acquirer for late-stage C5aR assets and a comparable benchmark for cross-border biopharma valuation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

InflaRx social profiles

Digital presence

InflaRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InflaRx leadership team

Management profile

Number of profiles

Profiles20 records

InflaRx subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

InflaRx funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InflaRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InflaRx

What does InflaRx do?

InflaRx is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutics targeting the complement system's C5a and C5aR signaling pathway. Its lead authorized product is GOHIBIC (vilobelimab), an intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for treating COVID-19 in hospitalized adults on mechanical ventilation or ECMO. Its pipeline lead is izicopan (INF904), an oral small molecule C5aR1 inhibitor in development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select renal diseases.

Is InflaRx a public or private company?

InflaRx is a public company. It is classified as public and is currently operating.

When was InflaRx founded?

InflaRx was founded in 2007. It employs 11 to 50 people.

Where is InflaRx based?

InflaRx is headquartered in Jena, Germany, in the Europe region.

How does InflaRx make money?

Two revenue lines are on record. GOHIBIC (Vilobelimab) Emergency Use is the primary driver. The others are licensing and Royalties (BDB-001/China).

Who are InflaRx's main competitors?

Direct peers on record are ChemoCentryx (Amgen), Alexion (AstraZeneca Rare Disease), Apellis Pharmaceuticals and Omeros Corporation. BioCryst Pharmaceuticals is listed as an emerging player. Broad incumbents are Swedish Orphan Biovitrum (Sobi), Amgen, AstraZeneca, Takeda Pharmaceutical and Novartis.

Does InflaRx have an API?

No public API is recorded for InflaRx.

What industry is InflaRx in?

InflaRx's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAHAA, Immunoglobulins (IVIG/SCIG). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewInflaRx N.V. Stock 12‑Month Price Target Cut to $7.62, Implies 551% UpsideAnalysts' average price target for InflaRx N.V. fell from $8.34 to $7.62, implying about 551% upside from the Nov. 13 closing price. The consensus remains a Buy across seven analysts, with no Holds or Sells.Defense WorldHead-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX)A head-to-head comparison of InflaRx and Travere Therapeutics evaluates profitability, institutional ownership, and analyst ratings. InflaRx beats Travere on 10 of 15 factors, with higher probable upside from its $7.43 target price versus Travere's $68.45. InflaRx's higher revenue and lower P/E ratio favor it as the more affordable stock.Seeking AlphaInflaRx N.V. (IFRX) Analyst/Investor Day TranscriptInflaRx held an analyst/investor day on November 3, 2026, with CEO Niels Riedemann and CFO Thomas Taapken discussing its AAV treatment strategy and izicopan development. The call focused on the evolving treatment landscape and unmet need in AAV, with no specific financial or operational details disclosed.MarketBeatInflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan TrialsInflaRx plans two Phase II trials for its C5a receptor antagonist izicopan in ANCA-associated vasculitis, focusing on kidney protection and steroid reduction. The company expects about 35 patients per arm in the placebo-controlled trial, with a global peak-sales opportunity of $1.65 billion. It also targets aHUS and IgA nephropathy studies by 2027-2028.Seeking AlphaInflaRx GAAP EPS of -€0.02 (NASDAQ:IFRX)InflaRx reported Q3 GAAP EPS of -€0.02. As of September 30, 2026, cash and cash equivalents rose to €81.3 million from €16.0 million a year earlier. The stock closed at $1.62, down 8.5%.American Banking and Market NewsInflaRx (IFRX) Projected to Post Quarterly Earnings on TuesdayInflaRx will report Q3 2026 earnings on Tuesday, November 3rd, with analysts expecting a loss of $0.07 per share and revenue of $0.01 million. The company's last EPS of -$0.11 missed estimates by -$0.04, and analysts project -$0.31 EPS for the current fiscal year. Analysts have an average rating of Moderate Buy with a price target of $7.43.MarketBeatInflaRx (IFRX) Expected to Announce Quarterly Earnings on TuesdayInflaRx is expected to announce Q3 2026 earnings on Tuesday, November 3rd, with analysts projecting a loss of $0.07 per share and revenue of $0.01 million. The company's stock opened at $1.73, and analysts have an average rating of Moderate Buy with a consensus target price of $7.43.The future of tradingInflaRx’s Izicopan Reduces Kidney Injury in Preclinical StudiesInflaRx presented preclinical results at Kidney Week 2026 showing oral izicopan reduced kidney injury in hamster models. Treatment improved kidney function markers and tissue damage, though reductions in kidney fibrosis were not statistically significant. Structural modeling suggested potentially lower drug-interaction risk than avacopan.MarketBeatInflaRx N.V. (IFRX) - What Are Brokerages Thinking About This Stock?Analysts rate InflaRx N.V. with a consensus Moderate Buy, with an average 1-year price target of $7.43. The stock opened at $1.59, and institutional ownership stands at 42.39%. The company's lead product is vilobelimab, targeting complement-mediated inflammatory diseases.American Banking and Market NewsCritical Analysis: TScan Therapeutics (NASDAQ:TCRX) and InflaRx (NASDAQ:IFRX)InflaRx and TScan Therapeutics are compared on profitability, valuation, and analyst ratings. InflaRx has higher earnings but lower revenue, while TScan has higher institutional ownership and a higher potential upside. Analysts favor TScan, citing its higher upside potential.